The role of pazopanib on tumour angiogenesis and in the management of cancers: A review
DK Chellappan, J Chellian, ZY Ng, YJ Sim… - Biomedicine & …, 2017 - Elsevier
Pazopanib is a relatively new compound to be introduced into the chemotherapy field. It is
thought to have decent anti-angiogenic properties, which gives an additional hope for the …
thought to have decent anti-angiogenic properties, which gives an additional hope for the …
[HTML][HTML] Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma
MJ Méndez-Vidal, Á Molina, U Anido… - BMC Pharmacology and …, 2018 - Springer
Background Pazopanib is indicated in the first-line treatment of metastatic renal cell cancer
(mRCC). The aim of this study was to review the efficacy, safety, and pharmacokinetics of …
(mRCC). The aim of this study was to review the efficacy, safety, and pharmacokinetics of …
[HTML][HTML] Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development
Background Antineoplastic therapy with the tyrosine kinase inhibitor pazopanib in patients
with advanced/metastatic renal cell carcinoma (mRCC) has been associated with …
with advanced/metastatic renal cell carcinoma (mRCC) has been associated with …
A network meta‐analysis of efficacy and safety of first‐line and second‐line therapies for the management of metastatic renal cell carcinoma
What is known and objective Metastatic renal cell carcinoma (mRCC) is the most common
type of kidney cancers. Disease‐specific survival for mRCC has been significantly improved …
type of kidney cancers. Disease‐specific survival for mRCC has been significantly improved …
Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
K Numakura, Y Muto, S Naito, S Hatakeyama… - Cancer …, 2021 - Wiley Online Library
Although combination immune checkpoint inhibitor (immuno‐oncology [IO]) therapy is the
first‐line treatment for metastatic renal cell carcinoma (mRCC), it mostly causes resistance …
first‐line treatment for metastatic renal cell carcinoma (mRCC), it mostly causes resistance …
Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib
LE Zucca, MAM Matushita, RJ da Silva Oliveira… - … Oncology: Seminars and …, 2018 - Elsevier
Background Renal cell carcinoma (RCC) represents 2%–3% of all cancers of the Western
countries. Currently, sunitinib, a receptor tyrosine kinase inhibitor, particularly of PDGF and …
countries. Currently, sunitinib, a receptor tyrosine kinase inhibitor, particularly of PDGF and …
[HTML][HTML] A clinical prediction model for predicting the risk of liver metastasis from renal cell carcinoma based on machine learning
Z Wang, C Xu, W Liu, M Zhang, J Zou… - Frontiers in …, 2023 - frontiersin.org
Background Renal cell carcinoma (RCC) is a highly metastatic urological cancer. RCC with
liver metastasis (LM) carries a dismal prognosis. The objective of this study is to develop a …
liver metastasis (LM) carries a dismal prognosis. The objective of this study is to develop a …
[HTML][HTML] Human liver stem cell-derived extracellular vesicles enhance cancer stem cell sensitivity to tyrosine kinase inhibitors through Akt/mTOR/PTEN combined …
V Fonsato, M De Lena, S Tritta, A Brossa, R Calvetti… - Oncotarget, 2018 - ncbi.nlm.nih.gov
It is well recognized that Cancer Stem Cells (CSCs) sustain the initiation, the maintenance
and the recurrence of tumors. We previously reported that extracellular vesicles (EVs) …
and the recurrence of tumors. We previously reported that extracellular vesicles (EVs) …
Clinical pharmacology of anti-angiogenic drugs in oncology
P Gougis, J Wassermann, JP Spano, N Keynan… - Critical Reviews in …, 2017 - Elsevier
Abnormal vasculature proliferation is one of the so-called hallmarks of cancer. Angiogenesis
inhibitor therapies are one of the major breakthroughs in cancer treatment in the last two …
inhibitor therapies are one of the major breakthroughs in cancer treatment in the last two …
Systemic therapy in metastatic renal cell carcinoma: emerging challenges in therapeutic choice
A Parmar, B Sander, GA Bjarnason… - Critical Reviews in …, 2020 - Elsevier
The treatment landscape for metastatic renal cell carcinoma (mRCC) has undergone a
substantial evolution in the past decade, with a dramatic increase in the number of available …
substantial evolution in the past decade, with a dramatic increase in the number of available …